Effect of dienogest on estrogen-induced nitric oxide production in human umbilical vein endothelial cells and endothelium-dependent vasodilatation in postmenopausal women

Menopause

Volumn 17, Issue 3, 2010, Pages 615-621

  Henmi, Noriko ^a   Takahashi, Kazuhiro ^a   Amita, Mitsuyoshi ^a   Takata, Keiko ^a   Ohta, Tsuyoshi ^a   Tsutsumi, Seiji ^a   Takahashi, Toshifumi ^a   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Dienogest; Endothelial cells; Flow mediated dilatation; Nitric oxide

Indexed keywords

DIENOGEST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROGESTERONE; PROTEIN KINASE B;

ADULT; ARTICLE; BRACHIAL ARTERY; CELL FUNCTION; CELL PROLIFERATION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; FEMALE; FLOW RATE; HUMAN; HUMAN CELL; POSTMENOPAUSE; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN; VASODILATATION;

BLOOD FLOW VELOCITY; BRACHIAL ARTERY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; NANDROLONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POSTMENOPAUSE; UMBILICAL VEINS; VASODILATION;

EID: 77952288418     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181d273c7     Document Type: Article

References (35)

1. Wiliams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81: 1680-1687.
2. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
3. Antunes CM, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979;300:9-13.
4. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in post-menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
6. Weiner CP, Lizanoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994;91:5212-5216. (Pubitemid 24177823)
7. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxypro-gesterone acetate on endothelium-dependent vasodilation in postmeno-pausal women receiving estrogen. Circulation 2001;104:1773-1778.
8. Hisamoto K, Ohmichi M, Kurachi H, et al. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 2001;276:3459-3467.
9. Oishi A, Ohmichi M, Takahashi K, et al. Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 324:193-198.
10. Endrikat J, Graeser T, Mellinger U, Ertan K, Holz C. A multicenter prospective, randomized, double-blind placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1 mg estradiol valerate/2 mg dienogest on hot flushes in postmenopausal women. Maturitas 2007;58:201-207.
11. von Schoultz B. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment. Climacteric 2003; 6:24-32.
12. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogester-one interferes with ovarian steroid protection against coronary vaso-spasm. Nat Med 1997;3:324-327.
13. Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:2154-2159.
14. Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2007;73:222-231.
15. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52: 2745-2756.
16. Kimura C, Oike M, Koyama T, Ito Y. Impairment of endothelial nitric oxide production by acute glucose overload. Am J Physiol Endocrinol Metab 2001;280:E171-E178.
17. Ohmichi M, Kanda Y, Hisamoto K, et al. Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas 2003;44: 125-131.
18. Takahashi K, Mori-Abe A, Takata K, et al. Raloxifene improve the ovariectomy-induced impairment in endothelium-dependent vasodilata-tion. Menopause 2007;14:656-661.
19. Hisamoto K, Ohmichi M, Kanda Y, et al. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem 2001;276: 47642-47649.
20. Mendelsohn ME, Karas RH. Mechanisms of disease: the protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340:1801-1811.
21. Simoncini T, Mannella P, Fornari L, et al. Differential signal trans-duction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745-5756.
22. Graser T, Koytchev R, Muller A, Oettel M. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000;2:109-118.
23. Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000;50:397-404.
24. Ware S. Pharmacological profile of progestins. Maturitas 2004;47: 277-283.
25. Khorram O, Han G. Influence of progesterone on endometrial nitric oxide synthase expression. Fertil Steril 2009;91(5 Suppl):2157-2162.
26. Simoncini T, Fu XD, Caruso A, et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 2007;22:2325-2334.
27. Simoncini T, Caruso A, Garibaldi S, et al. Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate. Obstet Gynecol 2006;108:969-978.
28. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J 2007;21:265-273.
29. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399:597-601.
30. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601-605.
31. Heidi L. Endothelial vasodilator production by uterine and systemic arteries. Estrogen and progesterone effects on eNOS. Am J Physiol Heart Circ Physiol 2001;280:H1699-H1705.
32. Gracia-Cardena G, Fan R, Shah V, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998;392:821-824.
33. Russell KS, Haynes MP, Caulin-Glaser T, Rosneck J, Sessa WC, Bender JR. Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J Biol Chem 2000;275: 5026-5030.
34. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothe-lial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-824.
35. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vasc Pharmacol 2006; 45:268-276.